Clove Oil
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Clove Oil: Initial Repurposing Screening — No Active Predictions Available
One-Sentence Summary
Clove Oil (DrugBank ID: DB11338) is a naturally derived substance from Syzygium aromaticum, widely recognised in traditional and complementary medicine for its antiseptic, analgesic, and antimicrobial properties. No TxGNN repurposing predictions have been generated for this compound at this stage, and no formal approved indications are on record in the South African (SAHPRA) medicines register. Without predicted indications, clinical trial evidence, or supporting literature, this candidate cannot advance to full evidence synthesis and is currently classified as Hold pending additional data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indications on record |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — TxGNN prediction run not yet completed |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
South Africa Market Information
Clove Oil (DB11338) is currently not registered with SAHPRA and holds no active product licences in South Africa. It does not appear on the Essential Medicines List (EML). No dosage form, route of administration, or approved indication data is available from the local regulatory record.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction pipeline has not yet generated repurposing candidates for Clove Oil, and the compound has no SAHPRA-registered products or approved indications in South Africa. There is insufficient data to conduct a meaningful repurposing evaluation at this time.
To proceed, the following is needed:
- TxGNN prediction run: Execute the KG and deep-learning prediction pipeline for DB11338 to generate candidate indications with confidence scores
- Mechanism of action (MOA): Retrieve full pharmacological profile from DrugBank (eugenol-mediated pathways, receptor targets, and enzyme interactions)
- Regulatory label review: Source the SAHPRA Professional Information (PI) or equivalent international label (EMA/US FDA) to document approved indications, warnings, and contraindications
- Drug interaction profile: Conduct a formal DDI assessment given the absence of interaction data in the current evidence pack
- Global market status review: Confirm whether Clove Oil or its primary active constituent (eugenol, DB11338) holds approval in any jurisdiction, which may inform evidence level and feasibility of a South African regulatory pathway
Disclaimer: This report is intended for research purposes only and does not constitute medical advice. Any repurposing candidate identified through TxGNN requires clinical validation before application. All findings should be interpreted by qualified healthcare professionals in accordance with applicable South African regulations.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.